Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Genton, P.
Right arrow Articles by Dravet, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Genton, P.
Right arrow Articles by Dravet, C.
Neurology 2000;55:1106-1109
© 2000 American Academy of Neurology
Articles

Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?

P. Genton, MD, P. Gelisse, MD, P. Thomas, MD and C. Dravet, MD

From the Centre Saint Paul (Drs. Genton, Gelisse, and Dravet), Marseille; and the Clinique Neurologique (Dr. Thomas), Hôpital Pasteur, Nice, France.

Address correspondence and reprint requests to Dr. Pierre Genton, Centre Saint Paul, 13258 Marseille 09 France; e-mail: piergen{at}aol.com

BACKGROUND: Juvenile myoclonic epilepsy is a frequent form of idiopathic generalized epilepsy that is usually and easily controlled by valproate monotherapy. However, juvenile myoclonic epilepsy is often misdiagnosed, and some drugs, especially carbamazepine and phenytoin, may have an aggravating effect.

OBJECTIVES: To determine the risk of aggravation of juvenile myoclonic epilepsy in patients treated with carbamazepine and phenytoin.

METHODS: Among 170 consecutive patients with juvenile myoclonic epilepsy (104 female, 66 male) referred between 1981 and 1998, the authors retrospectively found 40 patients (23%) who had received carbamazepine or phenytoin (duration of epilepsy at referral, 1 to 34 years; mean ± SD, 13.8 ± 8.5 years; follow-up, 3 to 50 years; mean ± SD, 16.4 ± 11 years).

RESULTS: Twenty-three patients (57.5%) experienced aggravation of seizures, whereas 6 (15%) apparently benefited from these drugs. There was no effect in the remaining 11 cases (27.5%). Carbamazepine was prescribed to 28 patients: 19 (68%) had aggravated symptoms, including myoclonic status in two; 4 (14%) were improved, one in association with valproate and one in association with valproate and phenobarbital. Phenytoin was prescribed in 16 cases: 6 (38%) had aggravation and 2 (12%) were improved, including one in association with phenobarbital. Vigabatrin was given in only one case, in association with carbamazepine, and provoked a mixed absence and myoclonic status.

CONCLUSIONS: Among commonly prescribed anticonvulsants, carbamazepine appears to have the strongest aggravating potential in patients with juvenile myoclonic epilepsy, whereas the aggravating effect of phenytoin is less prominent. Aggravation was mostly in the form of increased myoclonic jerks.




This article has been cited by other articles:


Home page
 NeurologyHome page
B. Baykan, E. A. Altindag, N. Bebek, A. Y. Ozturk, B. Aslantas, C. Gurses, I. Baral-Kulaksizoglu, and A. Gokyigit
Myoclonic seizures subside in the fourth decade in juvenile myoclonic epilepsy
Neurology, May 27, 2008; 70(22_Part_2): 2123 - 2129.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Noachtar, E. Andermann, P. Meyvisch, F. Andermann, W. B. Gough, J. Schiemann-Delgado, and For the N166 Levetiracetam Study Group
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures
Neurology, February 19, 2008; 70(8): 607 - 616.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
P. Thomas, L. Valton, and P. Genton
Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy
Brain, May 1, 2006; 129(5): 1281 - 1292.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
V. Biton, B. F. D. Bourgeois, and for the YTC/YTCE Study Investigators
Topiramate in Patients With Juvenile Myoclonic Epilepsy
Arch Neurol, November 1, 2005; 62(11): 1705 - 1708.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
C. Marini, L. Parmeggiani, G. Masi, G. D'Arcangelo, and R. Guerrini
Nonconvulsive Status Epilepticus Precipitated by Carbamazepine Presenting as Dissociative and Affective Disorders in Adolescents
J Child Neurol, August 1, 2005; 20(8): 693 - 696.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
A. Prasad, R. I. Kuzniecky, R. C. Knowlton, T. E. Welty, R. C. Martin, M. Mendez, and R. E. Faught
Evolving Antiepileptic Drug Treatment in Juvenile Myoclonic Epilepsy
Arch Neurol, August 1, 2003; 60(8): 1100 - 1105.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
R Renganathan and N Delanty
Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed
Postgrad. Med. J., February 1, 2003; 79(928): 78 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
P. Genton and P. Gelisse
Juvenile Myoclonic Epilepsy
Arch Neurol, September 1, 2001; 58(9): 1487 - 1490.
[Full Text] [PDF]

Home page
 NEJMHome page
A. Primavera, L. Roccatagliata, F. Langendorf, T. R. Browne, and G. L. Holmes
Epilepsy
N. Engl. J. Med., August 9, 2001; 345(6): 467 - 469.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by AAN Enterprises, Inc.